

Index

- absent bile duct syndrome, 213
- adenoma, *see hepatic*
- adrenal insufficiency, 86, 332
- adrenocorticotrophic hormone (ACTH), 138, 150, 331
- adult FA patient, 156, 264-274, 300-304; diabetes and vascular health, 268-269; gynecologic and fertility issues, 268; hematological issues, 266-267; psychosocial issues, 271-272; solid tumors in, 267-268; transition of care of, 118, 269-271
- agranulocytosis, 72
- alanine transaminase (ALT), 70-71, 87, 89-90, 233, 332, 335, 365
- albumin, 91
- alcohol, risks from use, 91, 203, 224, 251-252, 254, 261, 267, 272, 298, 302
- Alexander Graham Bell Association for the Deaf and Hard of Hearing, 176
- alkaline phosphatase (ALP), 90, 333, 335
- allergies, 203
- alternative medicine, 94, *see also vitamins, minerals, and herbal remedies*
- American Academy of Audiology, 176
- American Academy of Otolaryngology, 176
- American Diabetes Association, 148-149
- American Society of Blood and Marrow Transplantation, 224
- American Speech-Language-Hearing Association, 176
- amniocentesis, 286-287, 333
- anal atresia, 46, 77, 79
- androgens, 57-60, 64-66, 72, 333; androgen-responsive “acquired” aplastic anemia, 38; effect of androgens on: endocrine function, 157-158, glucose metabolism, 147, growth, 137-138, 157-158, insulin resistance 145, lipids, 130, liver, 60, 88-92, *see also hepatic*, menses, 121-122, and thyroid, 141; late effects from, 225; masculinizing side effects of, 58-59, 157; pregnancy, use during, 123; risks and side effects of, 57-60; transplant, use prior to, 183-186, 198-199, 202-203
- anemia, 66-67, 72, 127, 184, 252, 281, 333; aplastic, 33, 37-38, 46, 49, 52, 129, 183-184, 190, 211, 335; autoimmune hemolytic anemia, 50, 335
- anesthesia, *see pain*

- anticonvulsant therapy, risks of, 158
- anus, anal atresia, 46, 77, 79; ectopic, 77, 342; imperforate, 35, 38, 353
- aperistalsis, 213, 334
- appetite, 140; glucocorticoids, effect on, 158; stimulants, 85-86; supplemental feeds, 83-84
- arm lengthening, see *forearm lengthening*
- arthritis, 70, 72
- aseptic necrosis of bone or joints, see *avascular necrosis*
- aspartate transaminase (AST), 87, 89-90, 233, 335, 365
- asthma, 204
- autosomal recessive inheritance, 33, 275-277, 335, see also *genetic counseling*
- avascular necrosis, 60, 214, 216, 227, 336
- azoospermic, 268
- bacteremia, 229
- beta cell dysfunction, 146-147, 159
- betel nut chewing, 251
- biliary, bilirubin, 88, 90-91, 186, 210, 233, 336; hyperbilirubinemia, 213, 351
- bladder abnormalities, 36, 202, 204, 210, 212
- bleeding, 72, 91; esophageal, 84; from duodenal intubation, 80; from fish oil (omega-3 fatty acid), 94; from gastroesophageal reflux, 78; from ginkgo, 204; from hepatic adenoma, 90; hemorrhagic cystitis, 212; menstrual breakthrough, 124, 153; mucosal, 73; oral, 253; risk from drugs such as aspirin or ibuprofen, 73; side effect of cyclosporine A/tacrolimus, 214; uterine or menstrual, 123-124
- blind loop syndrome, 78, 337
- blood counts, 340; post-transplant, 193-194, 226, 232; to monitor bone marrow failure, 52, 54-56, 63, 65, 188
- body mass index, 82-83, 87, 122, 139, 228
- bone age, 137-138, 155, 232
- bone marrow, 337; aplasia, 178; aspiration, 74, 210, 337; biopsy, 50, 53, 61, 74, 188, 210, 232, 337; blast count, 184, 331, 337; cellularity, 50, 53, 61, 217; clinical monitoring and management of failure, 50, 53-56, 62-65; clonal abnormalities, see *clones*, *cytogenetic clonal abnormalities*; dysfunction, 49, 188; dysplasia, 50-51, 54, 184-185, 187, see also *myelodysplasia*; examination, 53, 74; onset of anemia, 66; severity of failure, 53; suppression of, secondary to H2-antagonists, 81; suppression of, secondary to infection, 50; transplant, see *transplant*;

- treatment options for failure, 56-61
- bone mineral density, see *osteopenia*, *osteoporosis*
- bowel, antegrade continence enema (ACE) procedures, 79; constipation, 73, 79, 80; encopresis, 79-80, 342; fecal incontinence, 79; malabsorption, 80, 83, 92, 140, 213; obstruction, 81; small bowel overgrowth, 79, 80
- BRCAl*, 284
- breast cancer susceptibility genes, 282
- breast pain, 283
- bronchitis, 204
- BUN (blood urea nitrogen test), 233, 337
- café au lait spots*, 34, 38, 44, 98, 204, 338
- cancer, early age of onset, 276, 281, 283; family history of, 224, 276; primary tumor, more than one, 276; risk in non-transplanted FA patients, 36; risk of, 37-38, 144, 217, 251, 268, 281, 284; secondary, 180, 190, 252-253; surveillance for, 33, 122, 126, 229-230, 255-257, 262, 280-281
- cancer, types of, acute lymphocytic (lymphoid) leukemia, 36, 50, 331; acute myelogenous leukemia (AML), 33, 35-38, 43, 49-52, 57, 64-65, 144-145, 180-181, 183-185, 190, 205, 331, 355; adenocarcinoma, 60, 332; anal, 39, 122, 125; astrocytoma, 280; bladder, 36; brain, 36, 39, 210, 230, 280; breast, 36, 39-40, 126, 129, 199, 230, 268, 276, 282-285; breast, male, 276, 282-285; cervical, 36, 38, 122-123, 125, 204, 267; chronic myelomonocytic leukemia, 36; colon, 36, 78; dermatofibroma, 36, 341; esophageal, 36-37; gastrointestinal, 268; genitourinary, 190, 194, 204; gynecological, 37, 122-123, 125-126, 144, 230; head and neck squamous cell carcinoma, see *head and neck squamous cell carcinoma*; human papillomavirus (HPV)-associated, 123, 126, 217, 230, 251, 253-254, 267, 350; kidney, see *cancer; renal*; liver (hepatocellular), 36-39, 58, 60, 90, 203, 349; lung, 36; lymphoma, 36, 356; medulloblastoma, 46, 230, 280, 357; melanoma, 204, 282; neuroblastoma, 36, 359; osteosarcoma, 36, 360; ovarian, 276, 282-283; pancreatic, 282; prostate, 276, 282-283; renal, 36, 210; retinoblastoma, 36, 364; skin, 230; stomach, 36; vaginal, 125; vulvar, 36, 39, 122, 125-126, 204, 267; Wilms tumor, 36, 39, 46, 230, 280, 369
- cardiac, arrhythmias, 68, 72; cardiac iron toxicity, 67-70, 72, 194; cardiac siderosis, 67; cardiovascular disease, 129-130, 228, 268; function, 186, 210; heart muscle injury, 212; tachycardia, 66; toxicity, late complication of transplant, 194; VACTERL

- cardiac anomalies, 46, 77
- cardiopulmonary, congenital defects, 35
- cardiovascular, vascular disease, 91, 129-130, 228, 268-269
- carpometacarpal, carpometacarpus, 98, 100, 107, 357
- carriers, as donor, 188; cancer risk in, 188, 275-276, 279, 282, 284-285; risk of FA in each pregnancy, 33; testing, 45, 278
- Center for International Blood and Marrow Transplant Research, 224
- Centers of Excellence for the treatment of FA, 193, 201
- central line, 83, 338, 350
- cervical esophagus, 255
- chest x-ray, 210, 256-257
- Children's Oncology Group, 223
- chimerism, mixed, 194, 226, 232-233, 267
- cholestasis, 92, 213, 338
- cholestatic jaundice, 58, 89
- chorionic villus sampling, 43, 286, 338
- chromosomal breakage or fragility test, 41-44, 98, 175, 202, 277, 339, 341; confirmatory FA diagnosis prior to HSCT, 210; test to rule out FA in HSCT donor, 187-188, see also *diagnosis of FA*
- cirrhosis, 67-68, 89, 213, 339
- clinical management checklist, 13-32
- clinical trials, 59, 87, 197, 241, 279
- clitoris, enlargement of, 58
- clones, cytogenetic clonal abnormalities, 210; cytokine use in patients with, 61, 187; growth hormone use in patients with, 144; significance of clone, 51-55, 184-185, 187-188
- colon interposition, 78
- colony stimulating factors, 33, 339, 341, 347-348; treatment with 60-61, 64-65, 187, 202
- colposcopy, 122, 125, 339
- comparative genomic hybridization (CGH), 52, 188, 339
- Complementary and Alternative Medicine of the National Institutes of Health, Office of, 94
- complementation groups, 219, 340; genotype-phenotype correlations, 280-281; relative frequency of, 39; testing for, 44, 202, 210, 276-278, 286
- consanguinity, 276, 340
- constipation, 73, 79-80
- contraception, hormonal, 123, 153-154
- corticosteroids, 137, 147

- cortisol sufficiency, see *endocrine system*
- cough, 78
- creatinine, 70, 210, 340, 347
- cryptorchidism, 154, 340
- cryptosporidium, 80
- cytokine therapy, see *colony stimulating factors*
- cytopenia, 33, 35, 39, 49-53, 184, 198, 200, 281, 341; androgen treatment for, 57-59
- D2 Western blots, 43-44
- deafness, 35, 174
- dental, caries due to chronic GvHD, 213; etiology of late effects, 225; gums, swelling or recession of, 214, 347; loose dentition, 253; non-alcohol mouthwash, use of, 254; oral hygiene, 254; orthodontic braces and oral appliances, 255; post-transplant guidelines, 229-230, 233; pre-transplant examination, 204, 210; surveillance for oral cancer, 204, 217, 255-257, 260-261, 267
- diabetes, 134; abnormal glucose or insulin metabolism in 145-147; adult care for, 156; as complication of iron overload, 68, 158 as complication of obesity, 87, 140, 150; insulin therapy for during HSCT, 149; isolated hyperinsulinemia, 149; post-transplant, 140, 225; risk of metabolic syndrome, 228; treatment of, 147-148
- diagnosis of FA, 33-48; examples of anomalies, 34-35; index of suspicion, 34-38; indications for testing, 38-41, 44-45, 175, 187, 251, 252; laboratory tests to diagnose, 40-45; risk of FA in each pregnancy, 33; testing siblings, see *siblings*; to rule out FA before hand surgery, 98
- diarrhea, 79-80, 83, 85, 91-92, 193, 204, 212-213, 218
- diet, dietary record, counseling, 83; dietary supplements, 93; healthy diet, 140, 149, 155, 224, 228; supplemental nutrition, 82-85; nutrition, see *nutrition*; obesity, overweight, see *obesity*, *overweight*; underweight, see *underweight*; weight loss diet, 87-88
- drugs, see *medications*
- duodenal, 35; duodenal atresia, 77-79, 203; duodenal intubation, 80
- DXA scan, see *osteopenia*, *osteoporosis*
- dyslipidemia, 86-87, 130, 139, 149-150, 156, 228, 265, 342, 351
- dysphagia, 213, 253, 342
- ear, absent ear canal (aural atresia), 168, 173; anatomy and function of, 165-166; cochlea, 165-166, 173; ear canal, 165-166, 168, 171, 173-174; ear malformations, 165, 175; eardrum, 20,

- 165-169, 173, 175; inner ear, 165-167, 173-174; middle ear, 35, 165-167, 169-170, 172-173, 175; outer ear, 165
- ear and hearing abnormalities in FA, 35, 165-177
- education, school, vocational, 170-172, 203, 211, 224, 231, 265, 271-272, 297
- elbow, 110, 112
- encopresis, 79-80, 342
- endocrine system, 134-164; androgen use, effect of on, see *androgens*; baseline evaluation, 134; bone mineral density, see *osteopenia, osteoporosis*; cortisol sufficiency, 138, 150, 340; diabetes, see *diabetes*; dyslipidemia, see *dyslipidemia*; endocrine issues in adults, 156-157; endocrine screening, 138; endocrinopathies in children and adolescents, 139; glucose abnormalities, see *glucose abnormalities*; growth hormone deficiency, see *growth*; height, see *height*; hematopoietic stem cell transplant (HSCT), effect on, 158-159; hyperglycemia, see *hyperglycemia*; hypothyroidism, see *thyroid*; insulin, abnormal metabolism of, see *insulin*; medications and treatments that affect endocrine function, 157-159; multiple hormonal deficiencies, effect on pituitary-hypothalamus, 150, see also *pituitary; hypothalamus*; multiple transfusion therapy, effect on, 158; puberty, effect on, see *puberty*
- endometrium, 124
- endoscopy, 84, 91, 255, 342
- eosinophilia, 213
- epiphyseal closure, epiphyses, 58-59, 109, 343
- erythrocyte sedimentation rate, 80, 343-344, 364
- erythroplakia, 256-257, 344, see also *head and neck squamous cell carcinoma*
- esophageal, 35-37, 78; atresia, 46, 77-78, 344; bleeding, 84; gastroesophageal reflux, see *reflux*; motility, 78; reflux, see *reflux*
- esophagus, cervical, 255
- ethnic background, examples of FA populations, 276-278
- European Fanconi Anemia Research Group, 281
- European Group for Blood and Marrow Transplantation (EBMT), 223-224
- exercise, 149, 224, 228
- eyes, decreased tear production, 230; epicanthal folds, 35, 343; eye pain, with GvHD, 213; hemorrhagic conjunctivitis, 213; keratoconjunctivitis with sicca, 213, 230, 354; lagophthalmos, 213, 354; Schirmers' test, 230, 364; Sicca Syndrome, 213, 365; small, close-set, 35

FANCC IVS4, 45-46, 136, 277, 281

Fanconi anemia, definition of, 33; DNA damage response pathway, 41, 341

Fanconi, Guido, 165

fecal incontinence, 79

fertility, infertility, 121-122, 128, 154, 156, 159, 265, 268, 275, 285-286; affected by HSCT, 127, 131, 154, 212, 225, 227

fever, 71, 73, 212-213

fibroblasts, 42-44, 175, 187, 210

fibroids, endometrial, 124

finger, index, 102-105

flow cytometry, 43, 188

fluid retention, 212, 218

fluorescent *in situ* hybridization (FISH), 52-53, 188, 345

fluoride treatment, 260-261

folate deficiency, 35, 39, 49, 83, 345

forearm lengthening, 115-117; distraction osteogenesis, 115-116; wrist fusion, 117

Founder effect or mutation, 45, 276-277, 284, 345; Africaans-speaking South African, 277; Afrikaner, 45; Ashkenazi Jewish, 45, 277; Black South African, 277; Brazil, 45; Finnish, 284; French Acadian, 277; Indian, 45; Israeli Arabs, 45; Japanese, 45, 277, 281; non-Ashkenazi Jewish Moroccan, 45; Portuguese-Brazilian, 277; Spanish Gypsy, 45; Sub-Saharan African Black, 45; Tunisian, 45

fructosamine levels, 146, 346

FSH (follicle-stimulating hormone), 138, 151, 232, 345, 347

galactorrhea, 158

gallbladder disease, 80

gastroesophageal reflux (GER), see *reflux*

gastrointestinal, 35, 71, 76-96, 121, 182, 213, 268; anal atresia, see *anal atresia*; appetite stimulants, see *underweight*; duodenal atresia, see *duodenal*; esophageal atresia, 78, see also *esophageal*; gastric emptying, 79, 81-82; gastritis, 81, 346; gastroesophageal reflux, see *reflux*; gastrointestinal symptoms, 79-82; gastrointestinal tract anatomic abnormalities, 77-78; gastroparesis, 86, 346; liver disease, see *hepatic*; nutrition as therapy, see *medications*; nutrition, supplemental, see *nutrition*; obesity and overweight, see *obesity and overweight*; peptic disorders, 81, 361; tracheoesophageal fistula, see *tracheoesophageal fistula*

gastro-jejunal tube, 84

- gastrostomy tube, 84-85, 91, 346
- genes and gene products, 39-40; *FANCA*, 39-40, 44-46, 277-278, 281; *FANCB*, 39-40, 44, 276; *FANCC*, 39-40, 44-46, 52, 136, 277-278, 281, 285; *FANCD1/BRCA2*, 39, 40, 44-46, 50, 52, 200, 202, 210, 225, 229-230, 233, 276, 278, 280-282, 284; *FANCD2*, 39-40, 43-44, 46; *FANCE*, 39-40, 278; *FANCF*, 39-40, 278; *FANCG (XRCC9)*, 39-40, 45-46, 277-278, 281; *FANCI (KIAA1794)*, 39-40, 46; *FANCL (BACH1, BRIP1)*, 39-40, 44, 276, 282, 284; *FANCL (PHF9/POG)*, 39-40, 44; *FANCM (hef)*, 39-40, 44; *FANCN/PALB2*, 39-40, 44, 46, 50, 52, 276, 281-282, 284-285
- gene therapy, 236-238; stem cell gene therapy, 240-242; stem cell therapy, 238-240
- genetic counseling, 275-290; genetic testing, 277-279, see also *mutation analysis*; *complementation groups*; mode of inheritance, 275-277; reproductive issues, 285
- genital warts, 123
- genotype-phenotype correlations, see *complementation groups*
- giardia antigen, 80, 347
- ginkgo, 204
- glomerular filtration rate (GFR), 186, 210, 347
- glucocorticoids, 147, 158, 227
- glucose abnormalities, abnormal lipid profile with glucose intolerance, 150; abnormal metabolism of, 134, 145-147; in adults, 156-157, 160, 268; during or post-HSCT, 158, 182, 228, 232; glucose intolerance assessment and monitoring, 87, 138, 140, 146-147, 359; incidence of in FA, 139; medications known to alter glucose metabolism, 86, 147; treatment of, 147-148
- gonads, gonadal function, abnormalities, 121, 138-139, 154, 347, 351; adults, hypogonadism in, 151, 156; effect of iron overload on, 68; Cytosax, effect on, 158; fertility, hypogonadism effect on, 128; HSCT effect on, 159, 191, 227; puberty, gonadal deficiency effect on, 151-152; screening for, 43, 138-139
- graft-versus-host disease, see *transplants, graft-versus-host disease*
- grieving process, 291, 304, 307; cognitive changes due to, 309; and the physician's role, 307-316; stages of, 308-310; physical changes due to, 309; self-destructive behavior from, 309
- growth, 82-83, 140, 152, 159-160, 200-201; androgen therapy effect on, 58, 157-158; bone therapy, 155; cortisol sufficiency, 138, 150, 340; hemoglobin level necessary for, 66; hormone deficiency, 134-135, 142-145, 227; hormone deficiency

post-transplant, 227-228; hormone, screening for, 138; incidence of low growth hormone, 139, 157; iron overload, effect on, 68; monitoring post-transplant, 224, 227, 232; pubertal delay, effect on, 122, 152, 153; radiation, effect on, 191; rate and bone maturation, 137-138; thyroid, effect on, 140-142, see also *thyroid*; treatment for, 144-145, 202, 228

growth plate, see *epiphyseal closure*

gynecologic and fertility issues in females, 121-133; abnormal uterine bleeding, 123-124; cancer, see *cancer* for specific type; cervical cytology testing, 122, 125; dysplasia, 123, 125, 131; fertility, see *fertility*; genital tract malformations, 121, 131, 154; gynecologic cancer, see *cancer*; *types of, gynecological*; exam, 122-123; gynecological issues related to HSCT, 127-128; human papillomavirus, see *cancer, types of, HPV-associated*; *vaccination/immunizations*; mammograms, see *mammography*; menopause, see *menopause*; menses, 35, 121-123; osteoporosis, see *osteopenia/osteoporosis*; pregnancy, see *pregnancy*; puberty, see *puberty*; uterine polyps, 124

gynecomastia, 283, 348

H2-antagonists, 50, 81, 348

hair, facial, pubic, scalp, 58, 212-214, 218

hand and arm differences, 97-120; emotional issues related to, 117-118; testing to rule out FA, 98

head and neck squamous cell carcinoma (HNSCC), 250-263, 267; age of presentation of, 252, 255; characteristics of in FA, 252; chemotherapy treatment of, 261; cytotoxic treatment, atypical response to, 252; diagnosis and evaluation, 255-257; dysplasia, 256-257; frequency of in FA, 253; human papillomavirus, see *vaccination/immunizations*; in non-transplanted patients, 36; incidence of, 250-252; non-FA SCC patients without normal risk factors, testing for FA in, 251-252; prevention of, 190, 217, 253-255; radiation treatment of, 259-261; risk for developing, 37, 144, 190, 251, 261; surgical treatment of, 258-259; surveillance for, 204, 217, 255-257, 260-261, 267; symptoms, presenting symptoms, 253; tobacco and alcohol use risks, see *smoking; alcohol*; T-stage, 259

hearing and ear abnormalities, 165-177; hearing and ear screening for family members, 175

hearing loss, amplification systems, 171-174; diagnostic tests, 167-168, 170, 175-176, 230-231, 335, 337; early identification and intervention for 170-171; iron chelator, possible effect of, 175; surgical management of, 172-174; types of, 35, 166-174, 261;

- useful resources for, 176-177
- heart, see *cardiac*
- heartburn, 85
- height, 159; adult height, estimates of, 137, 145; androgen use, effect on, 157-158; birth weight, effect on, 136; caloric intake, effect on, 139; early or delayed puberty, effect on, treatment for, 151-153; effect of *FANCC IVS4* mutation on, 136; growth rate, clinical observations of, 82, 137, 232; height prediction based on bone maturation, 137; hormone deficiencies, effect on, 135; parental height, 136; short stature, 34, 134-136, 144-145
- hematology, 35; clinical monitoring of bone marrow failure, 53-56, see also *bone marrow*; management guidelines for bone marrow failure, 62-65, see also *bone marrow*; significance of clonal abnormalities, 51-52, see also *clones*, *cytogenetic clonal abnormalities*; supportive care, 66-74; treatment of abnormalities, 49-75; treatment options for bone marrow failure, 56-61, see also *bone marrow*
- hematopoietic growth factor, 348, see also *colony stimulating factors*
- hematopoietic stem cell transplant, see *transplant*
- hemochromatosis, 348, see also *iron overload*
- hemoglobin, 349; as indicator for transplant, 184, 198; effects of high altitude on, 66; fetal hemoglobin, 38; glycosylated hemoglobin, 146, 347; hemoglobinopathy, 38, 349; monitoring of, 66; response to androgens, 58-59; response to cytokines, 60; response to transfusions, 67
- hemorrhagic conjunctivitis, 213
- hemorrhagic cystitis, 182, 212, 218
- hemosiderosis, 188
- hepatic, 88-92; adenomas, 36, 58, 60, 88, 90, 92, 332; alternate donor HSCT, liver function assessment for, 203, 210; androgens, effect on liver, see *androgens*; chronic hepatic GvHD of liver, 92, 213; cirrhosis, see *cirrhosis*; fatty infiltration of the liver, 91; hepatic fibrosis, 67-68, 70, 72, 91; hepatic sinusoids, 88, 349; hepatitis, 91-92, 189, 349; hepatocellular carcinoma, see *cancer*; *liver (hepatocellular)*; hepatoma, see *cancer*; *liver*; hepatomegaly, 88, 349; HSCT late effects, liver complications of, 91-92, 225, 233; iron overload, see *iron overload*; liver biopsy, 60, 68, 88-89, 91-92, 188, 226; liver enzymes, 90-91, 193; liver function and function tests, 60, 88, 91, 186, 203; liver transaminases, 60, 92; liver tumor, see *cancer*; *liver*

- (*hepatocellular*); non-alcoholic steatohepatitis, 87, 359; peliosis hepatis, 58, 88, 361
- herbal remedies, see *vitamins, minerals, and herbal remedies*
- heterozygote, 40, 45, 349
- high-risk behavior, 272, 298, 302, see also *alcohol; smoking*
- hip, dislocation, congenital, 35; dysplasia, 225
- hoarseness, 253
- homozygote, 45-46, 350
- human papillomavirus immunization, see *vaccinations/immunizations*
- humerus, 110
- hydrogen breath test, 80
- hyperbilirubinemia, 213, 351
- hyperglycemia, 139, 147, 150, 158-159, 216, 218, 351
- hyperlipidemia, see *dyslipidemia*
- hypertension, 130, 310; androgen use, side effect of, 58; associated with metabolic syndrome, 228; in adults, 265; in obese patient, 87; late effect of transplant, 214, 216, 218; portal hypertension, 213, 363
- hypertransaminasemia, 89
- hypogenitalia, 35
- hypogonadism, see *gonads, gonadal function*
- hypopharynx, 250, 252, 255, 259, 352, see also *head and neck squamous cell carcinoma*
- hypospadias, 35, 154, 352
- hypothalamus, 121, 142-143, 150-151, 159, 352
- hypothyroidism, see *thyroid*
- ileus, 213, 352
- immunizations, see *vaccinations/immunizations*
- immunoglobulin, 229, 233, 353
- impotence, 86
- Individuals with Disabilities Education Act (IDEA), 171
- infections, 189, 210, 215-216; adenovirus, 193; alternate donor HSCT, risks and timing of infections after, 215-217; aspergillosis, 189; bacterial, 73, 219; BK virus (BKV), 216; cryptosporidium, 80; cytomegalovirus (CMV), 67, 72, 180, 189, 193, 198, 207, 215-216, 341; Epstein-Barr virus (EBV), 189, 193, 216, 218, 251, 343; fungal, 74, 189, 193, 215-216, 218-219, 260; gastrostomy tubes, local infection from, 84; giardia antigen, 80; hepatitis, chronic viral, 92, 189; herpes or herpes simplex virus (HSV), 189, 215-216, 349; HIV, 209; infectious disease prophylaxis post-HSCT, 215; opportunistic, 80, 91, 214, 218; ova and parasites, 80; pneumocystis, 215, 362;

- prevention strategies, 215, 219; protozoal, 215; systemic, 80, 198, 215; urinary tract, 79; varicella zoster virus (VZV), 189, 216; viral, 215-216, 218-219; yeast, 215; *Yersinia enterocolitica*, 71
- infertility, see *fertility*
- insulin, abnormal lipid profile associated with insulin resistance, 150; abnormal metabolism of, 138-139, 145-147, 157; effect of androgens on, 147; insulin therapy during or post-HSCT, 149, 214, 218; insulin-like growth factor I, 143, 353; isolated hyperinsulinemia, 149, 159-160; screening for insulin levels, 87; treatment of diabetes with, 147-148
- insurance, problems, 201, 231, 272, 279, 303; insurance approval prior to donor search, 206
- International Fanconi Anemia Registry (IFAR), 264, 281-282
- in vitro* fertilization, 194, 219, 285-286, 354
- iron deficiency, 49
- iron overload, 67-72, 266, 348; chelation therapy, 69-72, 175, 338; clinical complications of, 68; effect of chelator on auditory function, 175; effect of on endocrine function, 158; iron supplements, risk of, 93; management of, 67-72; post-transplant, assessment and treatment of, 194, 225-227, 232-233; transfusions, effect of on, 67
- iron supplements, 93, 203
- jejunum, 35, 354
- Karnofsky Performance Status, 209, 354
- kidney, see also *renal system*; absent, horseshoe, hypoplastic or dysplastic, 35; dialysis, 214
- Klippel-Feil, 35, 354
- Lansky Status, 209, 354-355
- laryngoscopy, 262
- larynx, 250, 252, 255, 258, 355, see also *head and neck squamous cell carcinoma*
- late effects of transplant, see *transplant, late effects*
- leukoplakia, 256-257, 355, see also *head and neck squamous cell carcinoma*
- lichen planus, 213, 256-257, 356
- lipids, see *dyslipidemia*
- liver, see *hepatic*
- lungs, 36, 202, 212
- Lupron Depot therapy, 151
- macrocytic red cells or macrocytosis, 35, 38-39, 49, 188-189, 356
- magnesium, 214

- malabsorption, 80, 83, 92, 140, 213
- malignancy, see *cancer* or specific type of cancer
- mammography, 126, 283-284
- medications, antibiotics, 73-74, 215; chemopreventative drugs
 - in HNSCC, 254; delayed gastric emptying, possibly caused by, 79; diarrhea, possibly caused by, 80; fertility or ovarian function, post-transplant drugs effect on, 127; hearing loss, ototoxic drugs that may cause, 167, 175, 231, 360; hepatotoxic drugs, 91, 203; marrow failure, possibly caused by, 50, 53, 55; polypharmacy, 76, 363; that inhibit platelet function, 73
- menopause, 129-130, 357; hormone replacement therapy, 129-130; health risks, 129-130; premature, 39, 129, 154, 157, 225, 268
- menses, 35, 121-124, 128, 151, 153; suppression prior to transplant, 127
- mesenchymal cells, 238-240, 244, 357
- metabolic syndrome, 87, 149-150, 157, 228
- metacarpal, 34, 357
- microcephaly, 35, 38, 98, 357
- micrognathia, 35, 357
- midline defect, 139, 143, 150
- minerals, see *vitamins, minerals, and herbal remedies*
- mosaicism, 42-43, 175, 187, 199, 202, 210, 220, 241
- mouth sores, 212, 218
- mucositis, 182, 192
- mucus membrane integrity, 82
- mutation, 219, 276-277, 358; analysis, 43-45, 187-188, 202, 219, 276-279, 286; effect on height, 136; high-risk mutations, 46, 52, 199-200, 229-230, 278-282, 284-285; null mutation, 46
- myelodysplasia, myelodysplastic syndrome (MDS), 33, 35, 358; clonal abnormalities, significance of, 51-52, 185-186, 188; hematological care for, 49-55, 64-65; HSCT treatment for, 180-181, 183-185, 190, 194, 198-200, 211; indication to test for FA, 38
- myofasciitis, 213, 358
- nails, 107, 204, 213
- nasogastric tube, 84-85, 358
- nasojejunal tube, 84, 359
- nasopharynx, 250, 255, 359, see also *head and neck squamous cell carcinoma*
- National Comprehensive Cancer Network, 283
- National Institute on Deafness and Other Communication Disorders Information Clearinghouse, 177
- National Marrow Donor Program (NMDP), 63-64, 205-206

- nausea, 79-82, 212-213, 218, 313
- neurological, neurocognitive issues, 79, 84, 214, 225, 231; neuropsychology evaluation, 227, 232
- neutropenia, neutropenic, 49, 60, 68, 70-71, 73-74, 84, 175, 215, 359
- neutrophil count, absolute neutrophil count, 57, 60-61, 73, 184, 187, 198, 200, 331
- North American Survey (NAS), 264
- novel treatment options, 236-249
- nutrition, 76, 139-140; bone age, affected by, 138; diet, see *diet*; HSCT, assessment of nutrition prior or during, 91, 158, 202; marrow failure, affected by, 53; megaloblastic anemias, as caused by, 49; nutrition as therapy, 93-94; overweight, see *obesity*, *overweight*; post-HSCT nutritional issues, 225, 228; supplemental nutrition, 82-85; underweight, see *underweight*
- obesity, overweight, 87-88; 139-140, 149-150; central obesity, 228; diet, see *diet*; eating disorder, 87; glucocorticoids and anticonvulsant therapy, effect on, 158; impact of non-alcoholic steatohepatitis or liver disease on, 87; metabolic syndrome, see *metabolic syndrome*; nutrition, see *nutrition*; over-the-counter weight loss preparations, 88; sleep disorder or snoring related to, 87
- obliterative bronchiolitis, 213
- odynophagia, 253, 255, 359
- oral cavity, 250, 252, 255, 258-259, 261-262, see also *head and neck squamous cell carcinoma*
- oral dryness, 213; pain, 213, 253
- oropharynx, 250, 252, 255, 259, 267, 350, 360, see also *head and neck squamous cell carcinoma*
- osteopenia, osteoporosis, 124, 129-130, 134, 154-156, 159, 227; bone mineral density, 138-140, 152, 154-157, 159, 337; bone therapy, 155-156; dual energy absorptiometry (DXA) scan, 130, 138, 155-156, 227, 232, 342; T-score, 155, 367; Z-score, 138, 155, 369
- ova and parasites, 80
- ovarian, 127-128, 153; atresia, 121; failure, 39, 127, 157; function, effect of anticonvulsant therapy on, 158; tissue cryopreservation, 128
- oxidative stress, 93, 147, 243-244, 360
- pain, abdominal, 78-80, 91, 213; breast, 283; chronic, 202; colon interposition, pain from, 78; eye pain, with GvHD, 213; gastroesophageal reflux or tracheoesophageal fistula, pain from, 78; hepatomegaly, pain with, 88; intestinal stricture, pain with,

- 92; oral, with GvHD, 213; oral, throat or neck, 253; parotid gland, 212; sedation and analgesia for invasive procedures, 74, 313
- pancreas, 68, 140; pancreatic beta cell dysfunction, 159; pancreatic insufficiency, 92
- pancytopenia, 213, 360
- penis, 35, 58, 357
- peptic disorders, see *gastrointestinal issues*
- peritonitis, 84, 361
- phalanx, 105-107, 114, 361
- physicians, response to psychosocial issues, 305-306; role in grieving process, 310-316
- pituitary, 68, 138-140, 142-143, 150-151, 158-159, 362
- platelets, 53, 57, 72-73, 84, 94, 124, 198, 362
- pneumonia, 78
- polydactyly, pre-axial, 106
- polypharmacy, 76, 363
- potassium, 214
- pregnancy, 128-129, 268; uterine bleeding, 123; amniocentesis, 286-287, 333; androgen use during, 123; cryopreservation of embryos, sperm, and ovarian tissue, 128, 154; discuss childbearing options pre-transplant, 127; complications, 129, 225; preimplantation genetic diagnosis, see *preimplantation genetic diagnosis*; pre-natal testing, 33-34, 37, 62, 278-279, 363; reproductive options and family planning, 33, 127-128, 275-276, 283, 285
- preimplantation genetic diagnosis (PGD), 62, 194, 219, 285-287, 295-296
- proband, 45, 363
- prolactin, 158
- pseudomembrane formation, 213
- psychosocial issues, 225, 271-272, 291-306, 363; high-risk behaviors, 298, 302; recommendations for the physician, 305-306
- puberty, 151-153, 159, 363; breast buds, 122, 151; delay, 134, 138-139, 151-153, 156, 232, 363; early onset, 138, 151; relation of to age at transplant, 127; treatment benefits of for bone mineralization, 156
- pulmonary, complications, post-transplant, 186, 194; function, 186, 233
- quality of life, 66, 156, 160, 217, 224, 231, 233, 312, 314
- radial ray, 43, 364; abnormalities, 107-117, 364; carpectomy, 113, 338; centralization, 112-115; classification of radial deficiency,

- 107-110; external fixator 115-116; radial border, 97-99; radial deviation of the hand, 109; splint, 111-112, 114; stretching, 111-112
- radiation, sensitivity to, 56, 76-77, 80-81, 90, 125-126, 178-180, 186, 190-192; non-radiation imaging techniques, 76-77; pediatric and adult CT protocols, 77; total body irradiation, risks of, 127-128, 154; transplant preparative regimen without radiation, 190
- reactive airway disease, 204, 213, 364
- red cells, androgen effect on, 57; antibody testing, 50; iron overload, 67, 69; macrocytosis, 35, 38, 49; transfusions of, 67; transfusions for uterine bleeding, 124
- reflux, alkaline, 78; esophageal, 156; gastroesophageal (GER) 78, 81, 84, 156, 203, 346; ureteral, 203
- renal system, anomalies, 35, 121, 202, 212, 225; function, 183, 186, 210, 214, 233; hydronephrosis, 35, 210, 350; hydroureter, 35, 350; toxicity, 194; ultrasounds for *BRCA2* patients, 230, 233, 280
- ribs, 35
- scaphoid, 110
- school, education, 171, 224, 265-266, 270, 272, 297
- scoliosis, 35
- seizures, 214
- Self Help for Hard of Hearing People, 177
- sepsis, 180
- serology, 189
- serositis, 213
- Sertoli cell mass, 154, 365
- serum C-reactive protein, 80
- sexual, functioning, 265, 302-303; history, 202; sexually transmitted diseases, 123, 349
- short stature, see *height*
- siblings of FA patients, 292; genotype/phenotype correlations between FA siblings, 280; onset of bone marrow failure between FA siblings, 49; psychosocial demands on, 299-301; psychosocial functioning of FA patients compared to healthy siblings, 271-272; test to rule out FA in, 46, 175
- sinuses, sinusitis, 79, 84, 189, 204, 210
- skin, bullae, 213, 338; *café au lait* spots, 34, 98; cancer, 230; cutaneous (skin) GvHD, 213, 230; darkening of, 212; dermatology exams post-transplant, 233; desquamation, 213, 341; dry skin, 212; erythroderma, 213, 344; fibroblasts, 42-44, 175, 187,

- 210; hyperkeratosis, 213; hyperpigmentation, 34, 204, 351; hypopigmentation, 204, 352; lichen planus, 213, 256-257, 356; nevi, 204, 230, 359; rash, 70-71, 193, 204, 212-213; scleroderma, 213, 364; sun exposure effect on, 224, 230, 298
- smoking, cannabis (marijuana) 203; cigarettes, 203, 224, 251-252, 267, 298; second-hand smoke, 224
- spectral karyotyping (SKY), 52, 365
- speech and language therapy, 166, 170-171
- spina bifida, 35, 366
- Sprengel, 35, 366
- squamous cell carcinoma, see *cancer* or specific type of cancer
- St. John's wort, 204
- stroke, 129
- syndactyly, 35, 366
- tachypnea, 66
- testes, 35, 154
- thalassemia, 49, 67, 69, 179, 367
- thrombocytopenia, 49, 61, 68-73, 90, 123-124, 129, 367
- thromboembolism, 86, 367
- thumb, abnormalities of, 100-107; duplicated thumbs, 34, 106-107, 336; hypoplastic, floating (*pouce flottant*) or absent, 34, 98, 100-104, 175; opponensplasty, 98; pollicization, 98, 100, 102-105; triphalangeal, 34, 104-107
- thyroid, 368; adults, thyroid status in, 156-157; effect of anticonvulsant therapy or metaclopromide on, 158; hypoparathyroidism, 68, 158, 351-352; hypothyroidism, 68, 134-135, 140-142, 352; post-HSCT, function, 159, 191, 194, 212, 218, 225, 227
- thyroxine-binding globulin (TBG, T4, FT4), 140-142, 232, 368
- tobacco use, see *smoking*
- tracheoesophageal fistula, 35, 77-78, 203, 344, 369
- tracheomalacia, 78, 369
- transaminitis, 58
- transfusions, effect on iron overload, 67, 225-226; effect on transplant, 66-67, 184, 225-226; family members as donors, 67; for abnormal uterine bleeding, 123-124; HLA-typing and donor search before need for, 205; in adult non-transplanted patient with bone marrow failure, 266; menstrual suppression to decrease risk for transfusion prior to transplant, 127; platelet transfusions, 72, 357; pregnancy, transfusions related to, 129
- transplant, hematopoietic stem cell, see individual topics below
- transplant, androgen use prior to, see *androgens*
- transplant, childbearing options before, 127

- transplant, effect of clonal abnormalities, see *clones, cytogenetic clonal abnormalities*
- transplant, graft-versus-host disease (GvHD), 193, 216, 218, 348; chronic cutaneous, 230; chronic intestinal, 92; concurrent medication, effect on, 204; immune recovery affected by, 229; infection risk, 216, 218; management of, 192-193, 213-215; mortality from, 180, 214; ocular complications, see *vision*; prevention therapy side effects, 214; prophylaxis, 67, 179-181, 192-193, 211-215, 223-224; risk of, 182-183, 187, 190, 193; risk of carcinoma from, 57, 92, 192, 217, 229
- transplant, grafts, 189-192; engraftment, 189, 192-193; graft failure, prophylaxis and treatment, 180-182, 192-193, 211, 216-218
- transplants, immunizations post-transplant, see *vaccinations, immunizations*
- transplant, immunosuppression and immune reconstitution, 211, 214-216, 229, 233, 353
- transplant, late effects, 191, 193-194, 200, 216-17, 223-235; endocrine, 159, 194, 227; etiology of, 225; growth and development, 227; hematology, 226; immunology, 229; iron overload, 226, see also *iron overload*; malignancy risk, 229-230; metabolic syndrome, 228, see also *metabolic syndrome*; ocular complications, 230, see also *vision*; quality of life, 231
- transplant, matched sibling donor, 178-196; androgen and cytokine therapy prior to transplant, 186-187; cytoreductive regimens, TBI and non-TBI, 180-182, 190-191; indications for transplant, 183-186; overview and results of transplants, 178-179; post-transplant evaluation and complications of, 193-194; pre-transplant evaluation, patient and donor, 188-189; selection of donor, 187-188; source of stem cell graft, 189-190; timing of transplant, 62-65, 183
- transplant, organ function, effect on transplant, 68, 183, 186, 193-194, 198-199, 209, 228
- transplant, post-transplant: long-term follow-up, 224-233; quality of life, 231, see also *quality of life*
- transplant, radiation, effect on fertility, 127; risk factor for cancer, 217; sensitivity of FA patients to, 178; TBI cytoreductive regimen, unrelated donor, 211-212; TBI, side effects of, 212; TBI-based cytoreductive regimen, matched related donor, 180, 190, 368; thoraco-abdominal irradiation (TAI), 190; preparative regimen without radiation, 181, 190-191; preparative therapy side effects, 212

- transplant, selection of transplant center, 51, 62, 182-183, 186, 197, 199-201
- transplant, stem cell source, marrow, 189, 191-192, 198-199, 208-209; peripheral blood, 189-190, 208-209, 361; umbilical cord blood, 189, 192, 194, 198-199, 205-209, 287, 369
- transplant, transfusions prior to, see *transfusions*
- transplant, unrelated donor, 197-222; alternatives to, 219; collection of autologous stem cells, 217; donor search, insurance company approval, 206; donor search, selection, and timing of process, 63-64, 204-209; eligibility for transplant, 200, 210; exclusion criteria for, 209; indications for, 62-65, 198-201; infection post-transplant, 218-219; infectious disease prophylaxis, 215-216; initial assessment at transplant center, 201-204; overview, risk factors, and results of, 197-199
- transplant-related mortality and survival, 57, 63, 179-181, 183, 197-199, 214, 217, 219-220, 229, 251; peritransplant mortality, 183
- transposons, 237
- tumor, see *cancer* or specific type of cancer
- ulna, dysplastic, 109-110; in centralization, 112-115; lengthening of, 116
- underweight, appetite stimulants, 85-87; assessment of growth, 82-83; delayed gastric emptying, effect on, 81; duodenal atresia or stenosis correction, effect on, 78-79; malabsorption, effect on, 80, 83, 92, 140, 213; medical causes of, 79-81, 137-140; nutrition, see *nutrition*; nutritional causes of, 137, 139-140; poor oral intake, 79-82; supplemental nutrition for, 82-85
- urinary tract, congenital anomalies, 225; glucose in urine, 140; hemorrhagic cystitis, 182, 212, 218; ureteral reflux, 203; urine methylmalonic acid levels, 49
- uterus, 35, 121, 154, 336, 369; uterine or menstrual bleeding, 123-124
- vaccinations, immunizations, 203; hepatitis A and B, 91; HPV, 123, 126, 131, 229-230, 233, 254, 267; post-transplant, 229, 233; influenza, 229
- VACTERL, VACTERL-H, 38, 46, 77
- vaginal, dryness, vaginitis, strictures, 213
- virus, viral, see *infections*
- vision, 34; astigmatism, 35; cataracts, 35, 212, 218, 230; ischemia microvascular retinopathy, 230; keratoconjunctivitis sicca syndrome, 213, 230, 354; ocular complications post-transplant, 213, 225, 230; photophobia, 213, 362; strabismus, 35; vision

- loss, side effect of deferoxamine, 70-71; testing, 230
 - vitamins, minerals, and herbal remedies, 203; antioxidants, 93; calcium 130, 140, 155-156, 227, 232; fat-soluble vitamin levels, 91; folate, 35, 39, 49, 83, 345; fortified fruit juice or other beverages, 94; herbal remedies 203-204; magnesium, 214; megavitamin therapy, 93; potassium, 214; supplements, 83, 92-94, 156; vitamin B12, 35, 39, 49; vitamin C, 93-94; vitamin D, 130, 140, 155-156, 227, 232, 369; vitamins A and E, cancer risks of, 94; vitamins, effect of cholestasis on, 92; zinc, 83
 - vomiting, 78, 81, 85, 212-213, 218
 - weight, see *obesity*, *overweight*; *underweight*; *diet*; *nutrition*;
 - wheezing, 78
 - Wilms tumor, 36, 39, 46, 230, 280, 369
 - World Book search, 63
 - wrist, fusion, 117; radial deviation, 109-116
 - x-linked inheritance, 276, see also *genetic counseling*
-